We cure patients by developing innovative and clinically applicable diagnostics and therapeutic solutions
EdisBiotech is a company founded to save patients' lives and contribute to their health.
We have extensive experience in basic, translational, and clinical research on gastrointestinal diseases, which show a very high prevalence in South Korea.
Based on this, we are currently developing anti-cancer drugs (neutralizing antibodies, bi-specific antibodies, and antibody drug conjugates) and companion diagnostic tools to target biomarkers discovered from clinical samples.
We aim to take a step closer to diagnosing and overcoming diseases by utilizing technology, know-how, and domestic and international networks established through years of our path.
In addition, we endeavor to create a corporate culture that realizes the dreams of our employees and fulfills social responsibilities. We will grow into a global company that contributes to the healthy life of mankind.
CEOSeung Jae Myung
Career
- Graduate : Seoul National University, College of Medicine
- CEO, Edisbiotech
- Professor of Medicine, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine
- Director, Digestive Diseases Research Center, University of Ulsan College of Medicine
- KAIST adjunct professor (2017~2022)
- Director, Biomedical Research Center, Asan Institute for Life Sciences (2015 ~ 2020)
- President, Korean Association for the Study of Intestinal Diseases (KASID) (2022~2023)
- Seoul National Univerisy Bio CEO course 17th group (2017)
Research Experiences
- Director, Center for Bio-imaging of New Drug Development (2014~2019)
- Global networking and collaborator research (Dana Farber, Wisconsin, etc)
- Oncogenic mechanism and biomarker study in GI cancers
- Translational research on GI diseases (Therapeutics, diagnostics, molecular imaging)
- A number of government-funded grants (A grade)
- Over 450 SCI paper publications and over 100 clinical studies
- Over 40 patents
[domestic 22, PCT 5, international 12, utility model 2, trade mark 1]
Leadership
Eun Ok KimChief Operating Officer/Executive Director
- M.D. (Internal Medicine Specialist) /Ph.D. (Medical Microbiology)
- Clinical Advisory Physician, Asan Medical Center
- Aductive Professor of Internal Medicine, University of Ulsan
- Experienced in Regulatory Affairs (fluorescent dye, KFD)
- Experienced in Clinical Development (molecular imaging endoscopy, KFD)
Jun Sung LeeNew drug development/Executive Director
- POSTECH, Life Science, Ph. D
- Post-doc, The Rockefeller University, New York University
- Head of R&D, Neuramedy Co. Ltd
- Leader of Preclinical to Clinical development of monoclonal Antibody (FDA, MHRA)
- Experienced in early discovery, CMC, and non-clinical development of antibodies for oncology and neurological indication
SAB
Sanford D Markowitz
- Professor, Case Western Reserve University
- Case Gastrointestinal Cancer Genetics Program
- Lifetime research on the oncogenic mechanism and contribution to the development of diagnostics and treatments for gastrointestinal cancer
- A lot of valuable papers and Patents , Awarded many awards for his impact on research papers including 2 Science papers.
- Created "Rodeo Therapeutics" on the development of regenerative therapies utilizing targets identified in colorectal cancer
- In 2021, Rodeo Therapeutics was acquired by Amgen for $666 million and continues its drug development.
Sang Young Lee
- Attorney, Kim & Jang Law Firm
- Patent strategy